Tarsons Products Share Price

Medical Equipment company Tarsons Products announced Q4FY26 & FY26 results Standalone Financial Highlights: Total Income: Q4FY26: Rs 1,045.72 million, compared to Rs 994.16 million in Q4FY25 (YoY) and Rs 937.01 million in Q3FY26 (QoQ). FY26: Rs 3,619.59 million, compared to Rs 3,381.83 million in FY25. Profit for the period: Q4FY26: Rs 54.54 million, compared to Rs 157.29 million in Q4FY25 (YoY) and Rs 70.94 million in Q3FY26 (QoQ). FY26: Rs 226.58 million, compared to Rs 427.31 million in FY25. Earnings Per Share (EPS): Q4FY26: Basic and diluted EPS stood at Rs 1.03, compared to Rs 2.96 in Q4FY25 and Rs 1.33 in Q3FY26. FY26: Basic and diluted EPS stood at Rs 4.26, compared to Rs 8.03 in FY25. Consolidated Financial Highlights: Total Income: Q4FY26: Rs 1,275.37 million, compared to Rs 1,164.70 million in Q4FY25 (YoY) and Rs 1,163.45 million in Q3FY26 (QoQ). FY26: Rs 4,466.85 million, compared to Rs 4,083.74 million in FY25. Profit for the period: Q4FY26: Rs 41.81 million, compared to Rs 102.03 million in Q4FY25 (YoY) and Rs 50.36 million in Q3FY26 (QoQ). FY26: Rs 143.22 million, compared to Rs 297.70 million in FY25. Earnings Per Share (EPS): Q4FY26: Basic and diluted EPS stood at Rs 0.79, compared to Rs 1.92 in Q4FY25 and Rs 0.95 in Q3FY26. FY26: Basic and diluted EPS stood at Rs 2.69, compared to Rs 5.60 in FY25. Business Highlights: Auditors: The Board approved the re-appointment of M/s. Grant Thornton Bharat LLP as Internal Auditors for the Financial Year 2026-27. M/s. Price Waterhouse Chartered Accountants LLP issued an unmodified opinion on the standalone and consolidated financial results. Segment Reporting: The Group is primarily engaged in the manufacturing and selling of plastic laboratory products and certain scientific instruments, representing a single business segment. Managerial Remuneration: During FY26, the Company/Group paid excess remuneration to the Managing Director, Whole Time Director, and other Directors, exceeding the limits under Section 197 of the Companies Act, 2013 by Rs 41.39 million. The company is in the process of seeking shareholder approval for a waiver of this excess remuneration via a special resolution at the ensuing general meeting. Impact of New Labour Codes: The Group recognized an incremental impact of Rs 11.27 million (in the consolidated results) and Rs 11.27 million (in the standalone results) as an "Exceptional item" due to the implementation of new Labour Codes effective November 21, 2025. Result PDF

• Trendlyne
• 1 week ago

Medical Equipment company Tarsons Products announced Q3FY26 results Revenue: Rs 107.9 crore against Rs 95.7 crore during Q3FY25, change 13%. EBITDA: Rs 31.5 crore against Rs 29.6 crore during Q3FY25, change 6%. EBITDA Margin: 29.2% for Q3FY26. PBT: Rs 8.9 crore against Rs 8 crore during Q3FY25, change 11%. PAT: Rs 5 crore against Rs 5.3 crore during Q3FY25, change -6%. PAT Margin: 5.9% for Q3FY26. Aryan Sehgal, Promoter & Whole time Director, Tarsons, said: “Consolidated Revenue for Q3FY26 stood at Rs 108 crore, reflecting a growth of 12.8% YoY. EBITDA grew by 6.3% YoY to Rs 31.5 crore Q3FY26. PAT witnessed a decline primarily due to accelerated depreciation and higher finance costs arising from the capitalization of new facility at Panchla, whose revenue contribution will commence in the coming years. Cash PAT for 9MFY26 stood at Rs 78.9 crore, representing a robust 27.3% YoY growth. We are in the final phase of our capacity expansion, with commissioning scheduled for Q4FY26. With the addition of new capacities and an expanded product portfolio, we are well positioned to accelerate our growth journey by onboarding new customers, deepening relationships with existing clients, and scaling export revenues through a comprehensive offering tailored to diverse customer needs. Backed by over four decades of strong customer relationships and brand equity built by Tarsons, we remain optimistic about our growth trajectory in the years ahead. We remain committed to the long-term growth prospects of the industry and continue to invest through the current down cycle to strengthen our capacities and capabilities, positioning the company for sustainable growth over the next three to five years.” Result PDF

• Trendlyne
• 3 months 3 weeks ago

Medical Equipment company Tarsons Products announced Q1FY26 results Revenue: Rs 91.4 crore compared to Rs 84.8 crore during Q1FY25, change 8%. EBITDA: Rs 24.7 crore compared to Rs 18.8 crore during Q1FY25, change 32%. EBITDA Margin: 27.0% for Q1FY26. PAT: Rs 1.8 crore compared to Rs 4.0 crore during Q1FY25, change -56%. PAT Margin: 2.0% for Q1FY26. Aryan Sehgal, Promoter & Whole Time Director of Tarsons, said: We are pleased to report a YoY revenue growth of 10% and an EBITDA growth of 31% on a standalone basis. Domestic revenues in Q1FY26 saw a healthy uptick of approximately 12%, reflecting early signs of recovery in the life sciences industry and our ability to capture increased market share. While these signs of revival remain somewhat volatile, the current order pipeline and ongoing customer inquiries give us confidence in sustaining growth through FY26 and beyond. Profit After Tax for the current period was impacted due to accelerated depreciation following the capitalisation of our new facility. However, as revenue contribution from this plant ramps up, we expect to benefit from strong operating leverage, leading to improved overall EBITDA and PAT in the coming periods. Our Cash PAT in the interim grew by 38% on a standalone basis & by 44% on consolidated levels. With the addition of new product categories enabled by the commissioning of our new facility at Panchla, we will be positioned to address a broader market, supporting our growth ambitions and helping us outperform industry trends. Backed by the strong brand equity of Tarsons and our extensive pan-India distribution network, we are optimistic about achieving similar market share in these new categories as we currently command for our existing product portfolio. We remain committed to the industry's long-term growth prospects and have continued to invest through the down cycle to strengthen our capacities and capabilities, positioning ourselves for sustainable growth over the next 3–5 years. Backed by the strong brand equity of Tarsons and our consistent track record of delivering high-quality products, we are confident in our ability to capture greater market share in our existing product lines while accelerating the adoption of our newly introduced offerings.” Result PDF

• Trendlyne
• 9 months 2 weeks ago